CDC takes aggressive stance on postexposure prophylaxis. Centers for Disease Control and Prevention.
D000998:Antiviral Agents / Q000008:administration & dosage*; D017848:Blood-Borne Pathogens; D002487:Centers for Disease Control and Prevention, U.S.; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D019469:Indinavir; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000517:prevention & control*; D019259:Lamivudine; D016273:Occupational Exposure; D011725:Pyridines / Q000008:administration & dosage; D012307:Risk Factors; D014481:United States; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D015215:Zidovudine / Q000008:administration & dosage
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine